$1.30
-0.06 (-4.41%)
Open$1.35
Previous Close$1.36
Day High$1.41
Day Low$1.30
52W High$2.98
52W Low$1.03
Volume—
Avg Volume5.43M
Market Cap111.44M
P/E Ratio—
EPS$-1.93
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
+1,408.5% upside
Current
$1.30
$1.30
Target
$19.61
$19.61
$14.26
$19.61 avg
$29.32
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 114.7K | 619.1K | 29.02M |
| Net Income | -148,457,678 | -721,057,259 | -227,719 |
| Profit Margin | -130,006.0% | -123,505.7% | -0.8% |
| EBITDA | -153,882,361 | -788,927,376 | -290,155 |
| Free Cash Flow | — | — | -255,634 |
| Rev Growth | -81.5% | -81.5% | +16.9% |
| Debt/Equity | — | — | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $213.76 | +2.08% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $330.33 | -0.13% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $130.28 | -0.17% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $429.32 | -1.15% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $641.69 | +1.81% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.86 | -0.15% | 66.6 | 38.43B |